Loading
CAR-T Cell Therapy Research / Virus-based Gene Therapy Research · Journal article
Advanced Science · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept study demonstrating that niraparib plus anlotinib administered as bridging therapy enhances infiltration and antitumor activity of engineered dual-target CAR-T cells in mouse ovarian cancer models through vascular normalization and cGAS-STING pathway activation. The work is mechanistically sound but remains in animal models; clinical utility will be determined by the ongoing Phase 1 trial cited (NCT05141253).
Preclinical in vivo study in immunocompetent mouse models. Immunocompetent mice bearing ovarian tumors. Intervention: Niraparib (PARP inhibitor) plus anlotinib (tyrosine kinase inhibitor) as bridging therapy, followed by engineered dual-target mesothelin/CD19 CAR-T cells with TGFβ-resistance.
Niraparib plus anlotinib bridging therapy induces durable intratumoral T cell accumulation in immunocompetent mice Regimen activates cGAS-STING pathway, normalizes vasculature, and reduces fibrillar collagen deposition Engineered TGFβ-resistant, dual-target mesothelin/CD19 CAR-T cells show enhanced infiltration and antitumor activity when preceded by bridging therapy across multiple preclinical ovarian cancer models
No human safety or efficacy data reported; study is entirely preclinical
These preclinical findings support the rationale for the ongoing Phase 1 trial and offer a potential strategy to improve CAR-T cell therapy efficacy in solid tumors by preconditioning the tumor microenvironment without exposing CAR-T cells to concomitant drugs. Clinical utility remains unproven pending Phase 1 safety and efficacy results.
Preclinical mechanistic study in immunocompetent mice with engineered CAR-T cells, informing an ongoing Phase 1 trial; no human efficacy or safety data reported.
As stated by the source record.
These preclinical findings support the rationale for the ongoing Phase 1 trial and offer a potential strategy to improve CAR-T cell therapy efficacy in solid tumors by preconditioning the tumor microenvironment without exposing CAR-T cells to concomitant drugs. Clinical utility remains unproven pending Phase 1 safety and efficacy results.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Chimeric antigen receptor (CAR)‐T cell therapy is largely ineffective in most solid tumors, partially because of inadequate intratumoral trafficking. Bridging therapy, administered between leukapheresis and CAR‐T cell infusion, offers a distinct opportunity to control the disease and precondition the tumor microenvironment without directly exposing CAR‐T cells to concomitant drugs. Here, a poly (ADP‐ribose) polymerase (PARP) inhibitor combined with anlotinib is evaluated as bridging therapy for ovarian cancer. In immunocompetent mice bearing ovarian tumors, this regimen induces durable intratumoral T cell accumulation associated with activation of the cGAS‐STING pathway, vascular normalization, and reduced fibrillar collagen deposition. Furthermore, TGFβ‐resistant, dual‐target mesothelin (MSLN)/CD19 CAR‐T cells are engineered using a bait‐and‐switch strategy. Niraparib plus anlotinib administered as bridging therapy before CAR‐T cell infusion enhances CAR‐T cell infiltration and antitumor activity across multiple preclinical ovarian cancer models. These findings inform an ongoing phase I clinical trial (NCT05141253) evaluating the safety of these engineered CAR‐T cells following bridging therapy in patients with refractory MSLN‐positive solid tumors. Collectively, our findings support a clinically actionable bridging therapy with translational potential for potentiating CAR‐T cell therapy in ovarian cancer and highlight bridging therapy as a translational approach to improve CAR‐T cell access and efficacy in solid tumors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.